THE TAXOL SUPPLY CRISIS - NEW NCI POLICIES FOR HANDLING THE LARGE-SCALE PRODUCTION OF NOVEL NATURAL PRODUCT ANTICANCER AND ANTI-HIV AGENTS
THE TAXOL SUPPLY CRISIS - NEW NCI POLICIES FOR HANDLING THE LARGE-SCALE PRODUCTION OF NOVEL NATURAL PRODUCT ANTICANCER AND ANTI-HIV AGENTS
复制标题
DOI：
10.1021/np50100a001
复制
发表时间：
1993-10-01
影响因子：
5.1
通讯作者：
GREVER, MR
中科院分区：
文献类型：
--
作者：
CRAGG, GM;SCHEPARTZ, SA;GREVER, MR
在过去的30年里，美国国家癌症研究所参与了大多数被批准用于治疗癌症的药物的临床前和/或临床评价。NCI计划中考虑的许多新药物要么是天然产物，要么是天然产物的衍生物，对它们的开发至关重要的是药物供应问题。为了应对紫杉醇临床疗效的证明所带来的药物供应危机，NCI为那些对天然产物药物发现和开发感兴趣的人确定了几个重要的教训。因此，国家癌症研究所制定了计划，在证实具有抗肿瘤活性后，尽早启动探索性研究项目，大规模生产有前途的药物，以避免今后出现类似的供应危机。本文介绍了这些计划，并对紫杉醇的发展作了评述。
Over the past 30 years, the National Cancer Institute has been involved in the preclinical and/or clinical evaluation of the majority of those agents approved for the treatment of cancer. Many of the new agents under consideration in the NCI program are either natural products or derivatives of natural product leads, and of critical importance to their development is the issue of drug supply. In responding to the drug supply crisis which emerged with the demonstration of the clinical efficacy of taxol, the NCI has identified several important lessons for those interested in natural product drug discovery and development. As a result, the NCI has developed plans to avert similar supply crises in the future by initiating exploratory research projects for large-scale production of promising agents at the earliest possible point following the demonstration of confirmed antitumor activity. These plans, together with a review of the development of taxol, are presented in this paper.